For two specific groups, aspirin reduces the recurrence of colorectal cancer by around 50%.

Group a: 7.7% with aspirin vs 14.1% recurrence without aspirin.

Group b: 7.7% with aspirin vs 16.8% recurrence without aspirin.

What's nice is that these are real occurrences, not relative risk percentages. They don't need fuzzy numbers to make their results significant.

Of course, there's also the line at the bottom: "Severe adverse events occurred in 16.8% of aspirin recipients and 11.6% of placebo recipients." Ouch. So if you can make it past that increase in severe adverse events you'll be fine.

How severe? Worse than colon cancer?